# A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio

Source: https://onco.cc/trials/nct07833202/  
OnCo record `nct07833202` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of IN10018, tislelizumab, carboplatin and pemetrexed in lung cancer, run by Shanghai Jeyou Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation is a phase 3, randomised interventional study registered as NCT07833202 by Shanghai Jeyou Pharmaceutical Co., Ltd., with a registry enrolment figure of 416 participants, started 2026-10 and due to reach its primary completion in 2029-04. Interventions recorded: Sosimerasib in combination with IN10018; Tislelizumab + Carboplatin + Pemetrexed. Conditions listed: NSCLC. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV Non-squamous NSCLC disease". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07833202
- Phase: 3
- Setting: A Phase 3, Randomized, Positive Controlled, Open-Label and Multicenter Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for the Treatment of First Line Locally-advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Sponsor: Shanghai Jeyou Pharmaceutical Co., Ltd.
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT07833202: https://clinicaltrials.gov/study/NCT07833202

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [IN10018](https://onco.cc/drugs/in10018/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07833202.json